How is Nipah virus different from Coronavirus?

Nipah virus and coronavirus may seem similar in nature, but both the viruses are quite different in their own way. Today we will discuss how Nipah virus is different from Coronavirus

How is Nipah virus different from Coronavirus?

Two viruses, one state. Kerala is battling two different infections: the rise in coronavirus cases and the current outbreak of Nipah virus. However, as similar as they seem in nature, the two viruses are quite different in their own ways.

nipah virus

Nipah virus has been conclusively established as a zoonotic infection (an infectious disease that spreads between species, from animals to humans, or vice versa). The virus was isolated and identified in 1999. The disease is named after Sungai Nipahal, a village in Malaysia. In the case of this infection the host can be a pig, a fruit bat, dog, goat, cat, horse and possibly even sheep. In nature the virus is believed to be maintained by a “flying fox” (a type of fruit bat), indicating

Even twenty months after the first case was reported in Wuhan, China. Initially, it was believed to have originated from a wet market in Wuhan called the Wuhan Huanan Seafood Wholesale Market, but this theory has yet to be established. The debate over whether this was a “Made-in-a-Lab”, “Made-in-China” virus is still ongoing.


निपाह वायरस कोरोनावायरस से कैसे अलग है

There is no antidote in terms of treatment for both the infections. No antiviral drug has been developed yet. “Currently, there is no licensed treatment available for Nipah virus (NIV) infection. Treatment is limited to supportive care, which includes rest, hydration, and treatment of symptoms,” the Centers for Disease Control said. The CDC states that “there are immunotherapeutic therapies (monoclonal antibody therapy) that are currently under development and evaluation for the treatment of NiV infection.

A research study by the Coalition of Epidemic Preparedness Innovation (CEPI) tested several antiviral drugs, but only one demonstrated “good therapeutic efficacy in non-human primates.” In the context of the coronavirus, in October 2020, the Food and Drug Administration (FDA) approved the antiviral drug remdesivir to treat Covid-19. But it is a repurposed drug, and to date, no antiviral drug has been licensed to treat the virus.

But it is a repurposed drug, and to date, no antiviral drug has been licensed to treat the virus. Other reconstituted drugs are used, including tocilizumab. Repurposing FDA-approved drugs is one strategy for identifying rapidly deployable treatments for COVID-19. The World Health Organization says it does not recommend self-medication, including antibiotics, as a prevention or treatment for COVID-19

Nipah more lethal, less contagious, covid the exact opposite

Based on the assessment of the Global Virus Network, it has been estimated that the R0 (R naught) of Nipah virus was 0.43. R0 is a mathematical term that measures the average number of new infections that an infected person can cause in an otherwise nave population.

For infection to spread in a population, R0 must be greater than 1 (>1). When R0 is less than 1 (mortality rate is 45 per cent to 70 per cent and this is based on assessment made from the previous Nipah virus outbreak in Kerala, in which 17 out of 19 infected patients died. On the other hand, the R0 of Covid It fluctuates heavily and has been above the 1 percent mark several times in India and outside.

Leave a Reply

Your email address will not be published.